STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Tarsus (NASDAQ: TARS) will report third quarter 2025 financial results on Tuesday, November 4, 2025. The company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET to present results and a corporate update.

Participants may access the live webcast online; a recorded version will be posted on the company website shortly after the call and archived for approximately 90 days.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

-0.06% News Effect

On the day this news was published, TARS declined 0.06%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update.

Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
 
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com



FAQ

When will Tarsus (TARS) report Q3 2025 results?

Tarsus will report Q3 2025 results on Tuesday, November 4, 2025.

What time is the Tarsus (TARS) Q3 2025 webcast?

The live webcast is scheduled for 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025.

How can investors access the Tarsus (TARS) November 4 webcast?

Investors may access the live webcast via the company's website using the provided webcast link.

Will there be a replay of the Tarsus (TARS) Q3 2025 earnings call?

Yes. A recorded version will be posted shortly after the webcast and archived on the website for about 90 days.

What will Tarsus (TARS) cover during the November 4, 2025 call?

Tarsus will report its third quarter 2025 financial results and provide a corporate update.

Is there a dial-in number or only a webcast for the Tarsus (TARS) Q3 2025 report?

The announcement specifies a live webcast and archived recording; no dial-in details are provided in the notice.
Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

TARS Rankings

TARS Latest News

TARS Latest SEC Filings

TARS Stock Data

3.47B
39.75M
3.18%
118.17%
16.41%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
IRVINE